Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Change in Account Payables (2024 - 2025)

Historic Change in Account Payables for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to -$2.4 million.

  • Prelude Therapeutics' Change in Account Payables fell 104037.56% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year change of. This contributed to the annual value of $3.3 million for FY2024, which is 24559.47% up from last year.
  • According to the latest figures from Q3 2025, Prelude Therapeutics' Change in Account Payables is -$2.4 million, which was down 104037.56% from -$850000.0 recorded in Q2 2025.
  • In the past 5 years, Prelude Therapeutics' Change in Account Payables registered a high of $1.8 million during Q4 2024, and its lowest value of -$2.4 million during Q3 2025.